原发性甲状旁腺功能亢进(简称甲旁亢)并非少见。据报道,在美国发病率为27.7/10万,每年新发病例为3.5万～8.6万;在英国发病率为25/10万,平均每年有1万新发病例。经证实大多数高血钙病人,不是无骨病的原发性甲旁亢,就是非甲状旁腺恶性肿瘤,鉴别两者常有困难。诊断原发性甲旁亢依赖于在高血钙病人血清中,免疫反应甲状旁腺激素(PTH)浓度升高,但测定PTH操作困难,不能应用于每个高血钙病人。Watson等用差别分析(discriminant analysis)及选择性地用氢化可的松抑制试验,可不测定PTH而作出正确诊断(正确率达93%),这些技术在具有常规实验室的医院中均可做到。原发性甲旁亢的有效治疗是手术切除肿瘤。一些 Primary hyperparathyroidism (referred to as hyperparathyroidism) is not uncommon. According to reports, the incidence in the United States was 27.7 / 100,000, the annual incidence of 35,000 to 86,000 new cases; the incidence in the United Kingdom 25 / 100,000, an average of 10,000 cases of new cases each year. Confirmed that most of the patients with hypercalcemia, is not non-bone disease of primary hyperparathyroidism, non-parathyroid malignancy, the identification of both are often difficult. Diagnosis Primary hyperparathyroidism relies on an elevated immune parathyroid hormone (PTH) concentration in the serum of hypercalcemic patients, but the determination of PTH is difficult and can not be applied to every hypercalcemic patient. Watson et al. Used discriminant analysis and selective inhibition with hydrocortisone to make the correct diagnosis without PTH (up to 93% correct), which can be done in hospitals with routine laboratories . Effective treatment of primary hyperparathyroidism is the surgical removal of the tumor. some